Merck lowered its bid for Terns Pharmaceuticals after receiving new clinical-data signals, underscoring how ADC and oncology deals are increasingly sensitive to real-world efficacy and safety interpretation. The transaction value was adjusted downward to reflect clinical information that did not match earlier expectations, according to reporting describing why the final terms deviated from the pharma’s initial offer. The deal still fits the broader sector pattern of consolidating ADC and oncology platforms. For biotech dealmaking, the episode highlights a tight feedback loop between emerging clinical evidence and acquisition economics—especially when bidders seek to de-risk late-stage programs. Companies will likely face renewed diligence pressure on translational rationale, tolerability, and biomarker alignment as acquirers calibrate risk-adjusted pricing in a fast-moving M&A market.